Theralink Technologies, Inc.

Equities

THER

US88339Q1094

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 01:52:38 2024-04-29 pm EDT			5-day change	1st Jan Change
0.001 ^USD	0.00%		+25.00%	-33.33%

Feb. 20	Theralink Technologies, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	CI
Jan. 05	Theralink Technologies, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	CI

Theralink Technologies, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023

January 05, 2024 at 04:56 pm EST

Theralink Technologies, Inc. reported earnings results for the full year ended September 30, 2023. For the full year, the company reported sales was USD 0.606796 million compared to USD 0.567905 million a year ago. Net loss was USD 30.91 million compared to USD 12.74 million a year ago.

Basic loss per share from continuing operations was USD 0.01.

Latest news about Theralink Technologies, Inc.

Theralink Technologies, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 20	CI
Theralink Technologies, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Jan. 05	CI
Theralink Technologies, Inc. Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute?s Molecular Tumor Board	Nov. 03	CI
Theralink Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-21	CI
IMAC Holdings, Inc. announced that it has received $4.3 million in funding from Theralink Technologies, Inc. and other investors	23-07-25	CI
Theralink Technologies, Inc. Announces Chief Executive Officer Changes	23-06-27	CI
Theralink Technologies, Inc. Appoints Mick Ruxin as Chief Medical Officer	23-06-27	CI
Theralink Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-15	CI
Theralink Technologies, Inc. entered into a definitive agreement and plan of merger to acquire IMAC Holdings, Inc. for $0.9 million in a reverse merger transaction.	23-05-14	CI
Theralink Technologies, Inc. Announces Termination of Thomas Chilcott as Treasurer and Secretary	23-05-11	CI
Theralink Technologies, Inc. Announces CFO Changes	23-05-11	CI
Theralink Technologies, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	23-02-21	CI
Theralink Technologies, Inc. announced that it has received $4 million in funding from Cavalry Fund I Management, LLC	23-01-26	CI
Theralink Technologies Appoints Michael Vallone as Senior Director of Commercialization	23-01-09	CI
Theralink Technologies, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	22-12-29	CI
Theralink Technologies, Inc. Auditor Raises 'Going Concern' Doubt	22-12-28	CI
Patient selection for AstraZeneca, Daiichi breast cancer drug needs improvement, experts say	22-12-09	RE
Patient selection for AstraZeneca, Daiichi breast cancer drug needs improvement, experts say	22-12-09	RE
Theralink Technologies, Inc. Appoints Faith Zaslavsky, as President & Chief Operating Officer for its Precision Oncology Company	22-12-06	CI
Theralink Technologies, Inc. announced that it expects to receive funding from Cavalry Fund I Management, LLC	22-11-28	CI
Theralink Technologies, Inc. Appoints Mattia Cremona as Its Director of Its Biopharma Laboratory	22-11-07	CI
Theralink Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022	22-08-15	CI
Theralink Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022	22-05-23	CI
Theralink Technologies Expands Adoption of Its Precision Medicine Technology in the Biopharmaceutical Industry	22-04-19	CI
Theralink Technologies, Inc. Announces Board Appointments	22-04-06	CI

Chart Theralink Technologies, Inc.

Duration

Period

More charts

Company Profile

Theralink Technologies, Inc. is a proteomics-based, precision medicine company. The Company's technology, through its patented phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. Its LDT, the Theralink Assay for Breast Cancer, is utilized by oncologists across the United States to assist in making the targeted treatment plan for their patients with advanced breast cancer. The Company is also working on a second assay for advanced breast cancer that is planned to be pan-tumor for solid tumors across multiple tumor types, such as ovarian, endometrial, liver, head and neck, colorectal, lung, and prostate, among others. It provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both Food and Drug Administration approved and investigational drug treatments.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
THERALINK TECHNOLOGIES, INC.	-33.33%	6.15M
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	103B
REGENERON PHARMACEUTICALS, INC.	+1.62%	95.28B
ARGENX SE	+1.46%	22.15B
BIONTECH SE	-16.67%	21.02B
GENMAB A/S	-8.58%	18.15B
WUXI APPTEC CO., LTD.	-38.74%	16.73B
BEIGENE, LTD.	-13.21%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B

Bio Therapeutic Drugs